-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9

Benzinga·08/12/2026 09:29:58
Listen to the news
BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.